Clopidogrel Tablet, Film Coated
Product Images NDC 50268-184

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 50268-184). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

300mg (184 12)

Clopidogrel Tablets, USP are a prescription medication containing 391.5 mg of clopidogrel bisulfate, USP equivalent to 300 mg of clopidogrel. They come in 20 tablets (4 x 5) unit dose and are meant to be dispensed by a pharmacist with an accompanying medication guide to each patient. These tablets are manufactured by AVKARE, Inc. and should be kept at a controlled room temperature within the range of 15°C to 30°C (59°F to 86°F). The usual adult dosage should be determined by the physician and described in the prescribing information.*

FDA Label Image

Chemical Structure (Clopidogrel 01)

FDA Label Image

Figure 1 (Clopidogrel 02)

FDA Label Image

Figure 2 (Clopidogrel 03)

FDA Label Image

Figure 3 (Clopidogrel 04)

This is a chart showing the hazard ratio for patient baseline characteristics and on-study concomitant medications in the CURE study. The chart includes subgroups based on certain criteria such as gender, race, diabetes, previous medical history, and concomitant medications. There are also hazard ratios listed for each subgroup.*

FDA Label Image

Figure 4 (Clopidogrel 05)

This text appears to be a chart or graph which shows the percentage of deaths before first discharge for a group taking a placebo. The chart includes the number of deaths (1845) and the percentage of deaths (8.1%). The x-axis shows the number of days since randomization, up to 28 days. Additional information is not available.*

FDA Label Image

Figure 5 (Clopidogrel 06)

FDA Label Image

Figure 6 (Clopidogrel 07)

This is a statistical table presenting the results of a study on the use of Clopidogrel compared to a placebo. The study assessed the efficacy of Clopidogrel in different subgroups of patients classified by gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent given. The table displays the number of patients in each subgroup as well as the percentage of participants who received either Clopidogrel or the placebo. The last row shows the overall results of the study and the corresponding odds ratio.*

FDA Label Image

Figure 7 (Clopidogrel 08)

This is a graph showing the cumulative event rate (in percentage) of fatal or non-fatal vascular events between aspirin and clopidogrel over 18 months of follow-up. The y-axis ranges from 0 to 16% and the x-axis shows the months of follow-up. The data suggests that clopidogrel is associated with a lower cumulative event rate compared to aspirin. The statistical significance of the difference is indicated with p=0.045 at the bottom of the graph.*

FDA Label Image

Figure 8 (Clopidogrel 09)

This is a statistical table showing the results of a study comparing the efficacy of Clopidogrel and Aspirin in treating stroke patients. The table provides data on the number and percentage of patients who received each medication, as well as the hazard ratios for each year of the study. The hazard ratio represents the likelihood of an event occurring in one group compared to another. However, given the limited information, it is impossible to provide a more detailed description.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.